Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Fortress Biotech, Inc.

Ticker
FBIO
Sector
Industry
Report date
November 13, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments include earnings call transcripts for Q2 and Q3 2026, FDA approval of ZYCUBO for Menkes disease, and the sale of a Priority Review Voucher by Cyprium Therapeutics.

Recent developments:
  • Fortress Biotech held Q3 2026 earnings call providing operational and financial updates [N1].
  • Q2 2026 earnings call highlighted business progress and financial results [N2][N3].
  • Cyprium Therapeutics closed sale of a Rare Pediatric Disease Priority Review Voucher for $205 million in March 2026 [N4].
  • FDA approved ZYCUBO, the first treatment for Menkes disease in the U.S., announced in January 2026 [N8].
Overview

Fortress Biotech, Inc. operates as a biopharmaceutical company with a portfolio of subsidiaries including Journey, Mustang, Cyprium, and Avenue. The company focuses on drug development, commercialization, and strategic asset sales. Fortress maintains multiple shelf registration statements and at-the-market offering programs to support capital needs. It has a senior secured credit agreement with Oaktree Fund Administration, LLC, with amendments extending maturity and adjusting covenants. Fortress's subsidiaries contribute to revenue and cash flow through product sales, equity offerings, and asset monetizations. The company reported net income for the nine months ended September 30, 2026, supported by operational improvements and asset sales.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Fortress Biotech, Inc. is a biopharmaceutical company with multiple subsidiaries engaged in drug development and commercialization. The company has a complex capital structure with active equity offerings and secured credit facilities. Recent financials as of September 30, 2026, show cash and equivalents of $152.2 million and a current ratio of 2.93. Fortress reported net income for the nine months ended September 30, 2026, contrasting with prior period losses. Key recent developments include the sale of a Rare Pediatric Disease Priority Review Voucher by subsidiary Cyprium Therapeutics and FDA approval of ZYCUBO, a treatment for Menkes disease.

Scenarios for FBIO

Bull case model:

Fortress Biotech benefits from a diversified subsidiary structure enabling multiple revenue streams and asset monetizations. Recent FDA approvals and successful sales of Priority Review Vouchers provide liquidity and validate its development capabilities. The company's access to capital markets and credit facilities supports ongoing operations and growth initiatives. Operational improvements reflected in recent net income figures indicate progress in execution.

Bear case model:

The company faces risks related to its complex capital structure, including paused dividends on preferred stock affecting registration statement eligibility. Financial covenants tied to subsidiary net sales and liquidity impose operational constraints. The biopharmaceutical sector's regulatory environment and competitive pressures pose challenges to product commercialization and pipeline success. Dependence on asset sales and equity offerings for liquidity introduces execution risk.

Moat:

Fortress Biotech's moat derives from its diversified portfolio of biopharmaceutical subsidiaries, each with distinct drug development pipelines and commercial products. The company's ability to monetize assets such as Priority Review Vouchers and secure FDA approvals for novel treatments like ZYCUBO enhances its competitive position. Its access to capital markets through shelf registrations and ATM programs, combined with secured credit facilities, supports ongoing development and commercialization efforts. However, the biopharmaceutical industry remains highly competitive and regulated, requiring continuous innovation and capital.

Risks overview
Risks summary
The primary risks for Fortress Biotech relate to financing constraints due to paused dividends affecting registration eligibility, regulatory approval uncertainties, and execution challenges across its diversified subsidiary portfolio.
Risks details:

• Financing and Capital Structure Risks: Paused dividends on Series A Preferred Stock have temporarily limited Fortress's ability to use Form S-3 registration statements, affecting capital raising flexibility. The company must meet financial covenants related to liquidity and subsidiary net sales to avoid default under secured credit agreements.
• Regulatory and Commercialization Risks: FDA approvals are critical milestones; delays or failures in regulatory processes could impact product launches and revenue. Commercial success depends on market acceptance and competition in the biopharmaceutical sector.
• Operational and Execution Risks: The company's reliance on subsidiaries for revenue and cash flow requires effective coordination and execution across multiple entities. Asset sales and equity offerings are significant sources of liquidity, which may vary over time.

FINAL FORECAST FOR FBIO

Final take one line
Fortress Biotech exhibits very high visibility through detailed SEC filings and recent earnings disclosures, highlighting diversified biopharmaceutical operations with ongoing regulatory and financing activities.
Final take 12 to 24 month view

Business trends: Fortress Biotech's diversified subsidiaries continue development and commercialization of biopharmaceutical products, supported by asset monetizations and FDA approvals.
Execution milestones: FDA approval of ZYCUBO and sale of a Priority Review Voucher demonstrate regulatory and commercial progress; ongoing earnings calls provide operational transparency.
Key risks: Financing constraints due to paused dividends affecting registration eligibility, regulatory approval uncertainties, and execution challenges across multiple subsidiaries.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Fortress Biotech, Inc. operates in the biopharmaceutical sector with multiple subsidiaries including Journey, Mustang, Cyprium, and Avenue.
  • The company filed a shelf registration statement on Form S-3 effective May 30, 2024, but lost eligibility to use Form S-3 due to paused dividends on Series A Preferred Stock as of July 5, 2024; eligibility is expected to be regained upon filing the next Annual Report with dividends paid.
  • Fortress Biotech has multiple at-the-market (ATM) offering agreements through its subsidiaries Journey, Mustang, and Avenue, with varying availability and usage.
  • The company has a $50 million senior secured credit agreement with Oaktree Fund Administration, LLC, amended to extend maturity to June 30, 2028, with interest-only payments and financial covenants including minimum liquidity and net sales targets for Journey.
  • Cyprium Therapeutics, a subsidiary, sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million in March 2026, with 20% of proceeds payable to a U.S. National Institute; Cyprium declared a $118.6 million dividend in July 2026, paying approximately $95.4 million to Fortress.
  • Fortress Biotech reported cash and equivalents of $152.2 million and current assets of $210.4 million against current liabilities of $71.8 million as of September 30, 2026, resulting in a current ratio of 2.93 and cash ratio of 2.12.
  • For the nine months ended September 30, 2026, Fortress Biotech reported net income of $129.5 million compared to a net loss of $27.5 million for the same period in 2025.
  • Revenue for the three months ended September 30, 2026 was $19.2 million, with a net loss of $5.8 million and basic and diluted EPS of -$0.23 per share.
  • The company has contractual obligations including leases and secured debt, with a sublease agreement for office space expected to generate approximately $11.9 million in base rent through August 2031.
  • Fortress Biotech's FDA approval of ZYCUBO, the first treatment for Menkes disease in the U.S., was announced in January 2026.
  • Recent earnings call transcripts for Q2 and Q3 2026 provide detailed operational and financial updates.
  • The company has experienced significant cash flow changes due to asset sales, equity offerings, warrant exercises, and dividend payments from subsidiaries.
  • Fortress Biotech's subsidiaries have active equity offerings and ATM programs with proceeds contributing to the parent company's liquidity and operations.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
  • N1
  • N2
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-31 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Fortress Biotech (FBIO) Q3 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/fortress-biotech-fbio-q3-2026-earnings-call-transcript
  • N2 | 2026-08-14 | www.nasdaq.com | Fortress Biotech (FBIO) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/fortress-biotech-fbio-q2-2026-earnings-call-transcript
  • N3 | 2026-08-12 | www.nasdaq.com | Fortress Biotech Q2 Earnings Call Highlights | https://www.nasdaq.com/articles/fortress-biotech-q2-earnings-call-highlights
  • N4 | 2026-03-31 | www.nasdaq.com | Cyprium Therapeutics Closes Sale Of Rare Pediatric Disease PRV For $205 Mln | https://www.nasdaq.com/articles/cyprium-therapeutics-closes-sale-rare-pediatric-disease-prv-205-mln
  • N5 | 2026-03-25 | www.nasdaq.com | After-Hours Earnings Report for March 25, 2026 : JEF, CELC, FUL, EPAC, WS, MLKN, PGEN, BYND, MDV, DERM, FBIO, GCTS | https://www.nasdaq.com/articles/after-hours-earnings-report-march-25-2026-jef-celc-ful-epac-ws-mlkn-pgen-bynd-mdv-derm
  • N6 | 2026-02-05 | www.nasdaq.com | Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes | https://www.nasdaq.com/articles/cigna-q4-earnings-beat-estimates-higher-specialty-volumes
  • N7 | 2026-01-28 | www.nasdaq.com | Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums | https://www.nasdaq.com/articles/elevance-health-q4-earnings-beat-estimates-increasing-premiums
  • N8 | 2026-01-16 | www.nasdaq.com | Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch | https://www.nasdaq.com/articles/weekly-buzz-lyra-slashes-jobs-fda-okays-fbios-zycubo-bsx-acquire-pen-bctx-watch
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine